Summary & Overview
HCPCS J2770: Injection, Quinupristin/Dalfopristin 500 mg
HCPCS Level II code J2770 designates the 500 mg injection of quinupristin/dalfopristin, a combination streptogramin antibiotic used for serious systemic infections when susceptible organisms are present. Nationally, accurate coding of this injectable drug supports appropriate tracking of high-cost antimicrobials, informs utilization oversight, and affects hospital and infusion-site billing practices.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of quinupristin/dalfopristin, typical sites of service (hospital inpatient, hospital outpatient department, and infusion center), and the role of J2770 in claims for injectable antimicrobial therapy. The publication provides benchmarks for billing practice, common modifier usage noted for this service line, and considerations relevant to payers and providers managing specialty anti-infective administration.
Where input data are incomplete, the publication notes missing fields. The emphasis is on national applicability for coding, billing workflow implications, and clinical settings where J2770 is most likely used.
Billing Code Overview
HCPCS Level II code J2770 describes the injection of quinupristin/dalfopristin, a combined streptogramin antibiotic, in a 500 mg dose (150/350 formulation). The service represents administration of an intravenous antimicrobial agent intended for treatment of serious infections caused by susceptible organisms.
Service type: Injectable antibiotic administration (intravenous)
Typical site of service: Hospital inpatient, hospital outpatient, or infusion center
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related procedure codes.
Clinical & Coding Specifications
Clinical Context
A hospitalized adult patient with a severe, multidrug-resistant gram-positive bloodstream infection is prescribed intravenous quinupristin/dalfopristin. The drug is supplied as a 500 mg vial (J2770) and is administered via a central or peripheral IV line under inpatient or outpatient infusion center settings. Typical workflow: physician documents indication and orders dose based on weight and infection severity; pharmacy prepares the reconstituted and diluted infusion under sterile technique; nursing verifies order, obtains patient consent if required, confirms IV access and infusion pump programming, administers the infusion over the recommended time, and monitors for infusion reactions and line complications. Billing staff attach J2770 to the claim for the administered vial(s), append appropriate modifier(s) for payer adjudication (for example, reason for service, partial administration, or non-covered drug discarded), and link the claim to the primary ICD-10 diagnosis supporting medical necessity (such as complicated skin and soft tissue infection or bacteremia). Typical sites of service include inpatient hospital, outpatient hospital infusion center, emergency department when admitted or observed, and freestanding infusion centers. Patient scenario example: a 62-year-old male with prosthetic joint infection and documented vancomycin-resistant Enterococcus bacteremia receives J2770 in the hospital infusion suite with daily monitoring and infectious disease consultation.
Coding Specifications
| Modifier | Description | When to Use |
|---|